Written question asked by Lord Kamall (Conservative) on Tuesday, 10 March 2026, in the House of Lords. It was due for an answer on Tuesday, 24 March 2026. It was answered by Baroness Merron (Labour) on Monday, 23 March 2026 on behalf of the Department of Health and Social Care.
Thyroid Diseases: Medical Treatments
- Question
-
To ask His Majesty's Government what steps they are taking to address regional disparities in thyroid treatment, particularly variations in prescribing liothyronine between different integrated care boards.
- Answer
-
Integrated care boards (ICBs) are responsible for supporting appropriate prescribing in their areas, taking account of this guidance and individual clinical circumstances.
National Health Service regions cascaded the Items which should not be routinely prescribed in primary care policy guidance, which includes a reference to liothyronine, to ICBs.
Secondary information
- Type
- Written question
- Reference
- HL15394
- Session
- 2024-26
- Subjects
- Medical treatments Liothyronine Thyroid diseases
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-03-23 10:28:42 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15394
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15394
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2024-26/HL15394